Diabetech - Diabetes Tech, Research, News podcast

$11 Insulin for All? Inside the Nonprofit Rewriting U.S. Drug Prices

0:00
43:55
Recuar 15 segundos
Avançar 15 segundos

I sit down with Allan Coukell, Civica's Chief of Government Affairs & Public Policy Officer, to explore how its nonprofit insulin model and California’s CalRx partnership are bringing low-cost insulin—priced around $11 per pen and $30 per vial—to people nationwide, with or without insurance. We break down how pharmacy benefit managers, rebates, and the current drug pricing system have kept insulin prices high, and what’s finally shifting. We also dive into the rise of biosimilar insulin and how this approach could transform drug affordability far beyond diabetes. 

 

Learn about the Eversense 365 CGM

 

Learn about Omnipod 5 (today's sponsor)*

 

Join the Diabetech Newsletter

 

Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads

 

DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care. 

 

*10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

Mais episódios de "Diabetech - Diabetes Tech, Research, News"